摘要
目的:探讨枯草杆菌二联活菌对治疗亚临床肝性脑病的临床疗效和安全性。方法:80例亚临床肝性脑病患者随机分为枯草杆菌二联活菌(美常安)(n=40)和空白对照组(n=40),疗程60d,检测血氨浓度和进行数字连接试验来评价临床疗效,观察不良反应以评价其安全性。结果:治疗组患者的血氨浓度和NCT结果明显低于治疗前,且与对照组比较,差异有显著性意义(P<0.01)。治疗期间未发生严重不良反应。结论:应用枯草杆菌二联活菌对亚临床肝性脑病进行治疗,其疗效高,临床疗效好,不良反应较少。
Objective： To investigate the efficacy of the clinical treatment and to evaluate the security of Subclinical Hepatic Encephalopathy （SHE） by using live combined bacillus subtilis and enterococcus faecium. Methods： 80 SHE patients were randomly divided into treatment group （n=40） which treated with live combined bacillus subtilis and enterococcus faecium enteric-coated capsules and control group （n=40） which treated with blank capsules for sixty days. The efficacy of clinical treatment and the security were evaluated by the blood ammonia concentration and number connection test （NCT）. Results： After treatment, the blood ammonia concentration and NCT of treatment group were significantly lower than before. And there are also have significant differences compared to the control group （p〈0.01）. There is no serious adverse reactions during treatment. Conclution： Live combined bacillus subtilis and enterococeus faecium was a kind of effective and safe drug in treatment of SHE.
出处
《现代生物医学进展》
CAS
2012年第33期6489-6491,共3页
Progress in Modern Biomedicine
关键词
枯草杆菌二联活菌
亚临床肝性脑病
疗效
Live combined Bacillus Subtilis and Enterococcus Faecium
Subclinical Hepatic Encephalopathy
Therapeutic efficacy
